| Çö Àç ½á ºê ·¦ Àç °í ¼ö ·® |
|
|
|
| ½Ã ¾à ¸í |
Catalog No. |
Æ÷Àå´ÜÀ§ |
Àç °í ¼ö ·® |
| 17-AAG |
A-6880 |
1 g |
2 |
| Bafilomycin A1 |
B-1080 |
1 mg |
5 |
| Geldanamycin |
G-4500 |
250 mg |
1 |
| Geldanamycin |
G-4500 |
1 g |
2 |
| Genistein |
G-6055 |
1 g |
1 |
| Glycitein |
G-1152 |
5 mg |
1 |
| Glycitein |
G-1152 |
10 mg |
2 |
| Leptomycin B, Free Acid |
L-6100 |
100 ug |
1 |
| LY 294002 |
L-7962 |
5 mg |
1 |
| Rapamycin |
R-5000 |
50 mg |
5 |
| Rapamycin |
R-5000 |
100 mg |
4 |
| ½Ã ¾à ¸í |
Catalog No. |
Æ÷Àå´ÜÀ§ |
¼øµµ |
CAS No. |
| 9CI |
RidaforolimusR-7040 ÂüÁ¶ |
A-7696621
À̸í :
ºÐÀÚ·® : ; ºÐÀÚ½Ä :
¿ëÇØµµ : |
A-1803 |
10mg, 50mg, 100mg, 300mg |
>99% |
|
|
17-AAG
À̸í :Telatinib,17-(Allylamino)-17-demethoxygeldanamycin, 17-(Allylamino)geldanamycin, Tanespimycin
ºÐÀÚ·® : 585.69 ; ºÐÀÚ½Ä : C31H43N3O8
¿ëÇØµµ : Soluble in DMSO at 150 mg/mL; soluble in ethanol at 5 mg/mL; very poorly soluble in water; maximum solubility in plain water is estimated to be about 20-50 ¥ìM; buffers, serum, or other additives may increase or decrease the aqueous solubility. |
A-6880 |
250mg, 1g, 2g, 5g, 10g, 25g |
>99% |
[75747-14-7] |
| AB-1010 |
Masitinib, Free Base M-7007 ÂüÁ¶ |
| ABT-578 |
Zotarolimus, Z-9040 ÂüÁ¶ |
|
6"-O-Acetyldaidzin
ºÐÀÚ·® : 458.41 ; ºÐÀÚ½Ä : C23H22O10
¿ëÇØµµ :Soluble in DMSO, methanol or ethanol. |
A-6900 |
1 mg, 5mg, 10mg, 25mg |
>98% |
[71385-83-6] |
| Acetyldinaline |
CI-994, Free Base C-2606 ÂüÁ¶ |
|
6"-O-Acetylgenistin
ºÐÀÚ·® : 474.41 ; ºÐÀÚ½Ä : C23H22O11
¿ëÇØµµ :Soluble in DMSO, methanol or ethanol. |
A-3000 |
1 mg, 5mg, 10mg, 25mg |
>98% |
[73566-30-0] |
|
6"-O-Acetylglycitin
ºÐÀÚ·® : 488.44 ; ºÐÀÚ½Ä : C24H24O11
¿ëÇØµµ :Soluble in DMSO, methanol or ethanol. |
A-7860 |
1 mg, 5mg, 10mg, 25mg |
>98% |
|
| AG 490 |
Tyrphostin AG 490,T-9142 ÂüÁ¶ |
| AG 1478 |
Tyrphostin AG 1478,T-7310 |
| AG-013736 |
Axitinib, Free Base A-1107 ÂüÁ¶ |
| AGN-192024 |
Bimatoprost B-2777 ÂüÁ¶ |
| Alimta |
Pemetrexed, Disodium Salt, HeptahydrateP-7177 ÂüÁ¶ |
| 17-(Allylamino)-17-Demethoxygeldanamycin |
17-AAG, A-6880 ÂüÁ¶ |
| 17-(Allylamino)geldanamycin |
17-AAG, A-6880 ÂüÁ¶ |
| Alvespimycin |
17-DMAG, D-3440 ÂüÁ¶ |
| 2'-Amino-3'-methoxyflavone |
PD 98059, P-4313 ÂüÁ¶ |
| AMN-107 |
Nilotinib, N-8207 ÂüÁ¶ |
| 3-Angeloyl Ingenol |
Ingenol 3-Angelate, I-5900 ÂüÁ¶ |
| 3-Angelyl Ingenol |
Ingenol 3-Angelate, I-5900 ÂüÁ¶ |
| Anthra(1,9-cd)pyrazol-6(2H)-one |
SP600125, S-7979 ÂüÁ¶ |
| Anthrapyrazolone |
SP600125, S-7979 ÂüÁ¶ |
| Antibiotic AM-2282 |
Staurosporine, S-9300 ÂüÁ¶ |
| Antibioitic S 7481F1 |
Cyclosporin A, C-6000 ÂüÁ¶ |
| AP 23573 |
Ridaforolimus R-7040 ÂüÁ¶ |
| Armala |
Pazopanib, Free Base, P-6706 ÂüÁ¶ |
|
Ascomycin
ºÐÀÚ·® : 792.01 ; ºÐÀÚ½Ä : C43H69NO12
¿ëÇØµµ :Soluble in DMSO at 65 mg/mL; soluble in ethanol at 50 mg/mL with warming; very poorly soluble in water; maximum solubility in plain water is estimated to be about 10-50 ¥ìM; buffers, serum, or other additives may increase or decrease the aqueous solubility. |
A-1040 |
5mg, 25mg, 100mg, 300mg, 1g |
>99% |
[104987-12-4] |
| Ascotoxin |
Brefeldin A, B-8500 ÂüÁ¶ |
| AT-877 |
Fasudil, Monohydrochloride Salt, F-4660, HA-1077, Dihydrochloride Salt, H-2330 ÂüÁ¶ |
| ATS 1287B |
Leptomycin B, Free Acid, L-6100 ÂüÁ¶ |
|
Axitinib, Free Base
ºÐÀÚ·® : 386.47 ; ºÐÀÚ½Ä : C22H18N4OS
¿ëÇØµµ :Soluble in DMSO at 33 mg/mL; soluble in ethanol at 1.7 mg/mL with warming; very poorly soluble in water; maximum solubility in plain water is estimated to be about 10-50 ¥ìM; buffers, serum, or other additives may increase or decrease the aqueous solubility. |
A-1107 |
25mg, 50mg, 100mg, 200mg, 1g, 2g |
>98% |
|
| AY-22989 |
Rapamycin, R-5000 ÂüÁ¶ |
| AZD-0530 |
Saracatinib, Free Base S-8906 ÂüÁ¶ |
| B705008K112 |
Bryostatin 1, B-6697 ÂüÁ¶ |
| Baccatin III N-benzyl-¥â-phenylisoserine ester |
Paclitaxel, P-9600 ÂüÁ¶ |
|
Bafilomycin A1
ºÐÀÚ·® : 622.83 ; ºÐÀÚ½Ä : C35H58O9
¿ëÇØµµ :Freely soluble in DMSO; may react with methanol or ethanol, so these solvents are not recommended for stock solutions; very poorly soluble in water; maximum solubility in plain water is estimated to be about 5-10 ¥ìM; buffers, serum, or other additives may increase or decrease the aqueous solubility. |
B-1080 |
1mg, 5mg, 10mg, 25mg |
>95% |
[88899-55-2] |
| Bay 43-9006 |
Sorafenib, p-Toluenesulfonate Salt, S-8502 ¹× Sorafenib, Free Base, S-8599 ÂüÁ¶ |
| BAY-59-7939 |
Rivaroxaban S-8502 ¹× Sorafenib, Free Base, R-7199 ÂüÁ¶ |
| BAY u3405 |
Ramatroban, Free Acid R-7966 |
| Baynas |
Ramatroban, Free Acid R-7966 |
| N-Benzoyl-7-oxostaurosporine |
Stauprimide S-9344 |
| 4'-N-Benzoyl Staurosporine |
PKC412, P-7600 ÂüÁ¶ |
|
Bexarotene, Free Acid
À̸í :[Targretin] [Targretyn] [Targrexin] [LGD-1069] [LG 1069] [LG100069] [SR-11247]
ºÐÀÚ·® : 348.48 ; ºÐÀÚ½Ä : C24H28O2
¿ëÇØµµ :Soluble in DMSO at 65 mg/mL; soluble in ethanol at 10 mg/mL with warming; very poorly soluble in water; maximum solubility in plain water is estimated to be about 10-50 ¥ìM; buffers, serum, or other additives may increase or decrease the aqueous solubility. |
B-2422 |
100mg, 300mg, 500mg, 1g, 5g |
>99% |
[153559-49-0] |
| BEZ235 |
NVP-BEZ235, Free Base N-4288 ÂüÁ¶ |
| BFA |
Brefeldin A, B-8500 ÂüÁ¶ |
| BIBF1120 |
Vargatef, Free Base V-9077 ÂüÁ¶ |
Bimatoprost 
À̸í :[AGN-192024] [Lumigan] [Prostamide] [Latisse]
ºÐÀÚ·® : ; ºÐÀÚ½Ä :
¿ëÇØµµ : |
B-2777 |
1mg, 5mg, 10mg, 50mg |
>98% |
|
| BIRB 796 |
Doramapimod, Free Base, D-2744 ÂüÁ¶ |
| BMS-354825 |
Dasatinib, Free Base D-3307 ÂüÁ¶ |
|
Bortezomib
À̸í :[Velcade] [MG-341] [PS-341]
ºÐÀÚ·® : 384.24 ; ºÐÀÚ½Ä : C19H25BN4O4
¿ëÇØµµ :Soluble in DMSO at 200 mg/mL; soluble in ethanol at 200 mg/mL; soluble in water at 3 mg/mL; buffers, serum, or other additives may increase or decrease the aqueous solubility. |
B-1408 |
5mg, 10mg, 25mg,50mg, 100mg, 300mg , 1g |
>99% |
[179324-69-7] |
|
Bosutinib, Free Base
À̸í :
ºÐÀÚ·® : 530.45; ºÐÀÚ½Ä : C26H29Cl2N5O3
¿ëÇØµµ :Soluble in DMSO at 33 mg/mL; soluble in ethanol at 10 mg/mL with warming; very poorly soluble in water; maximum solubility in plain water is estimated to be about 10-50 ¥ìM; buffers, serum, or other additives may increase or decrease the aqueous solubility. |
B-1709 |
25mg, 50mg, 100mg, 200mg, 500mg, 1g |
>99% |
[380843-75-4] |
|
Brefeldin A
ºÐÀÚ·® : 280.36 ; ºÐÀÚ½Ä : C16H24O4
¿ëÇØµµ :Soluble in DMSO or ethanol. |
B-8500 |
10 mg, 25mg, 50mg, 100mg, 300mg, 1g |
>99% |
[20350-15-6] |
|
Bryostatin 1
À̸í :[B705008K112]
ºÐÀÚ·® : 458.41 ; ºÐÀÚ½Ä : C23H22O10
¿ëÇØµµ :Soluble in DMSO, methanol or ethanol. |
B-6697 |
10ug, 25ug, 100ug, 300ug, 1 mg |
>99% |
[83314-01-6] |
|
Bryostatin 2
ºÐÀÚ·® : 863.00 ; ºÐÀÚ½Ä : C45H66O16
¿ëÇØµµ :Soluble in DMSO or ethanol. |
B-3517 |
10 ug, 25ug, 100ug |
>99% |
[87745-28-6] |
|
Calyculin A
ºÐÀÚ·® : 1009.17 ; ºÐÀÚ½Ä : C50H81N4O15P
¿ëÇØµµ :Soluble in DMSO and ethanol; very poorly soluble in water; maximum solubility in plain water is estimated to be about 1-10 ¥ìM; buffers, serum, or other additives may increase or decrease the aqueous solubility .
ÁÖÀÇ:TUMOR PROMOTER. Gloves and mask should be worn when using this compound. Care must be taken to prevent contact through all routes of exposure |
C-3987 |
50ug, 100ug, 300ug, 1mg |
>98% |
[101932-71-2] |
| Campto |
Irinotecan, Hydrochloride Salt, Trihydrate, I-4122 ÂüÁ¶ |
| Camptosar |
Irinotecan, Hydrochloride Salt, Trihydrate, I-4122 ÂüÁ¶ |
| Camptothecin 11 |
Irinotecan, Hydrochloride Salt, Trihydrate, I-4122 ÂüÁ¶ |
|
Canertinib, Dihydrochloride Salt
À̸í :[CI-1033] [PD 183805]
ºÐÀÚ·® : 558.86 ; ºÐÀÚ½Ä : C24H25ClFN5O3.2HCl
¿ëÇØµµ :Soluble in DMSO at 100 mg/mL; soluble in ethanol at 1 mg/mL with warming; soluble in water at 10 mg/mL with warming; buffers, serum, or other additives may increase or decrease the aqueous solubility. Compound is somewhat unstable in HPLC sample solution at room temperature. |
C-1201 |
25mg, 50mg, 100mg, 200mg, 1g |
>99% |
[289499-45-2] |
| Capecitabin |
Capecitabine C-2799 ÂüÁ¶ |
Capecitabine
À̸í :[Xeloda] [Ro-9-1978] [Caxeta] [Capecitabin] [Capiibine]
ºÐÀÚ·® : ; ºÐÀÚ½Ä :
¿ëÇØµµ : |
C-2799 |
500mg, 1g, 2g, 5g, 25g |
>99% |
|
| Capecitabin |
Capecitabine, C-2799 ÂüÁ¶ |
| Capecytabine |
Capecitabine, C-2799 ÂüÁ¶ |
| Capiibine |
Capecitabine, C-2799 ÂüÁ¶ |
| Captabin |
Capecitabine, C-2799 ÂüÁ¶ |
| Caxeta |
Capecitabine, C-2799 ÂüÁ¶ |
| CC-5013 |
(R,S)-Lenalidomide, Free Base L-5499 ÂüÁ¶ |
| CCI-779 |
Temsirolimus, T-8040 ÂüÁ¶ |
| CDC-501 |
(R,S)-Lenalidomide, Free Base L-5499 ÂüÁ¶ |
| Celebra |
Celecoxib, C-1502 ÂüÁ¶ |
| Celebrex |
Celecoxib, C-1502 ÂüÁ¶ |
| Celecox |
Celecoxib, C-1502 ÂüÁ¶ |
|
Celecoxib
À̸í :[Celebrex] [Celebra] [Celecox] [Onsenal] [Solexa] [SC-58635] [YM-177]
ºÐÀÚ·® : 381.37 ; ºÐÀÚ½Ä : C17H14F3N3O2S
¿ëÇØµµ : Soluble in DMSO at 200 mg/mL; soluble in ethanol at 100 mg/mL; very poorly soluble in water; maximum solubility in plain water is estimated to be about 10-50 ¥ìM; buffers, serum, or other additives may increase or decrease the aqueous solubility. |
C-1502 |
300mg, 1g, 5g, 25g, 100g |
>99% |
[169590-42-5] |
| CellCept |
Mycophenolic Acid, Free Acid M-7800 ÂüÁ¶ |
| CEP-701 |
Lestaurtinib,L-6307 ÂüÁ¶ |
| Certican |
Everolimus, E-4040 ÂüÁ¶ |
| cFMS Receptor Tyrosine Kinase Inhibitor |
GW2580, Free BaseG-5903 ÂüÁ¶ |
| CGP41251 |
PKC412 P-7600 ÂüÁ¶ |
| CGP-57148B |
Imatinib, Methanesulfonate Salt, I-5508 ÂüÁ¶ |
| CGP-79787 |
Vatalanib, Dihydrochloride Salt, V-8303 ÂüÁ¶ |
|
Chelerythrine Chloride
ºÐÀÚ·® : 383.82 ; ºÐÀÚ½Ä : C21H18NO4Cl
¿ëÇØµµ : Soluble in water (5 mg/ml) or DMSO (>10 mg/ml). |
C-3030 |
5mg, 10mg, 25mg, 100mg |
>99% |
[3895-92-9] |
| CHIR-258 |
Dovitinib, Free Base D-3608ÂüÁ¶ |
| CI-940 |
Leptomycin B, Free Acid, L-6100 ÂüÁ¶ |
CI-994, Free Base
À̸í :[Tacedinaline] [Acetyldinaline] [Goe-5549] [Go 5549] [PD 123654]
ºÐÀÚ·® : ; ºÐÀÚ½Ä :
¿ëÇØµµ : Soluble in water (5 mg/ml) or DMSO (>10 mg/ml). |
C-2606 |
50mg, 100mg, 300mg, 1g, 5g |
>99% |
|
| CI-1033 |
Canertinib, Dihydrochloride Salt C-1201 ÂüÁ¶ |
| Ciclosporin A |
Cyclosporin A, C-6000 ÂüÁ¶ |
| CL-1957A |
Leptomycin B, Free Acid, L-6100 ÂüÁ¶ |
| CNF-101 |
17-AAG A-6880 ÂüÁ¶ |
| Cocarcinogen A1 |
Phorbol 12-Myristate 13-Acetate, P-1680 ÂüÁ¶ |
| Colforsin |
Forskolin, F-9929 ÂüÁ¶ |
| CP 127374 |
17-AAG, A-6880 ÂüÁ¶ |
| CP-358774 |
Erlotinib, Hydrochloride Salt E-4007 ÂüÁ¶ |
|
CP690550, Free Base
À̸í :[CI-1033] [PD 183805]
ºÐÀÚ·® : 312.37 ; ºÐÀÚ½Ä : C16H20N6O
¿ëÇØµµ :Soluble in DMSO. |
C-1377 |
10mg, 25mg, 50mg, 100mg, 500mg, 1g |
>99% |
[477600-75-2] |
| CPT-11 |
Irinotecan, Hydrochloride Salt, Trihydrate, I-4122 ÂüÁ¶ |
| CS-747 |
Prasugrel, Free Base P-6866 ÂüÁ¶ |
| CsA |
Cyclosporin A, C-6000 ÂüÁ¶ |
| CSF-1 Receptor Inhibitor |
GW2580, Free Base G-5903 ÂüÁ¶ |
| CT53518 |
Tandutinib, Free Base T-7802 ÂüÁ¶ |
| Cyanein |
Brefeldin A, B-8500 ÂüÁ¶/TD>
|
| CYC202 |
Roscovitine, R-1234 ÂüÁ¶ |
|
Cyclopamine, Free Base
À̸í :[11-Deoxyjervine]
ºÐÀÚ·® : 411.62 ; ºÐÀÚ½Ä : C27H41NO2
¿ëÇØµµ : Soluble in DMSO(4mg/ml), methanol (7mg/ml) or 2% ethanol (20mg/ml).
ÁÖÀÇ:TERATOGEN. Gloves and mask should be worn when using this compound. Care must be taken to prevent contact through all routes of exposure. Women of childbearing age should be extremely careful in handling cyclopamine! |
C-8700 |
25mg, 50mg, 100mg, 300mg, 500mg, 1g, 2g |
>99% |
[4449-51-8] |
|
Cyclosporin A
À̸í :[Cyclosporine] [Antibiotic S 7481F1] [Ciclosporin A] [Ramihyphin A] [CsA]
ºÐÀÚ·® : 1202.61 ; ºÐÀÚ½Ä : C62H111N11O12
¿ëÇØµµ : Soluble in DMSO or ethanol; (1 mL of ethanol will dissolve 160 mg). |
C-6000 |
1g, 5g, 10g, 25g, 100g |
>99% |
[59865-13-3] |
| Cyclosporine |
Cyclosporin A, C-6000 ÂüÁ¶ |
| D04014 |
Enzastaurin, Free Base E-4506 ÂüÁ¶ |
| D07086 |
RivaroxabanR-7199 ÂüÁ¶ |
| Dacplat |
Oxaliplatin, O-7111 ÂüÁ¶ |
|
Daidzein
À̸í :[4',7-Dihydroxyisoflavone] [7-Hydroxy-3-(4-hydroxyphenyl)chromone]
ºÐÀÚ·® : 254.24 ; ºÐÀÚ½Ä : C15H10O4
¿ëÇØµµ : Soluble in DMSO; very poorly soluble in other solvents. |
D-2946 |
1g, 5g, 10g, 25g, 100g |
>99% |
[486-66-8] |
|
Daidzin
À̸í :[4',7-Dihydroxyisoflavone, 7-O-¥â-D-glucopyranoside] [Daidzein, 7-O-¥â-D-glucopyranoside]
ºÐÀÚ·® : 416.38 ; ºÐÀÚ½Ä : C21H20O9
¿ëÇØµµ : Soluble in DMSO. |
D-7878 |
25mg, 100mg, 300mg, 1g |
>99% |
[552-66-9] |
|
Dasatinib, Free Base
À̸í :[BMS-354825] [Sprycel]
ºÐÀÚ·® : 488.01 ; ºÐÀÚ½Ä : C22H26ClN7O2S
¿ëÇØµµ : Soluble in DMSO at 200 mg/mL; very poorly soluble in ethanol; very poorly soluble in water; maximum solubility in plain water is estimated to be about 10 ¥ìM; buffers, serum, or other additives may increase or decrease the aqueous solubility. |
D-3307 |
500mg, 1g, 2g, 5g, 10g, 25g |
>99% |
[302962-49-8] |
| Decumbin |
Brefeldin A, B-8500 ÂüÁ¶ |
| Deforolimus |
Ridaforolimus R-7040 ÂüÁ¶ |
| 11-Deoxyjervine |
Cyclopamine, Free Base, C-8700 ÂüÁ¶ |
| 12-Deoxyphorbol 13-Acetate |
Prostratin, P-4462 ÂüÁ¶ |
|
12-Deoxyphorbol 13-Isobutyrate
À̸í :[dPB]
ºÐÀÚ·® : 418.52 ; ºÐÀÚ½Ä : C24H34O6
¿ëÇØµµ :Soluble in DMSO or ethanol. |
D-5571 |
1 mg, 5mg |
>99% |
[25090-74-8] |
|
12-Deoxyphorbol 13-Phenylacetate
À̸í :[dPP]
ºÐÀÚ·® : 466.57 ; ºÐÀÚ½Ä : C28H34O6
¿ëÇØµµ : Soluble in DMSO or ethanol. |
D-8660 |
1 mg, 5mg |
>99% |
[58821-98-0] |
| dFdC |
Gemcitabine, Hydrochloride Salt G-4177 ÂüÁ¶ |
|
(R,S)-2,3-Dihydrodaidzein
ºÐÀÚ·® : 256.25 ; ºÐÀÚ½Ä : C15H12O40
¿ëÇØµµ :Soluble in DMSO, methanol, or ethanol. |
D-9200 |
50mg, 100mg, 500mg |
>99% |
|
| 4',7-Dihydroxyisoflavone |
Daidzein, D-2946 ÂüÁ¶ |
| 4',7-Dihydroxyisoflavone, 7-O-¥â-D-glucopyranoside |
Daidzin, D-7878 ÂüÁ¶ |
| 4',7-Dihydroxy-6-methoxyisoflavone |
Glycitein, G-1152 ÂüÁ¶ |
| 17-(Dimethylaminoethylamino)-17-demethoxygeldanamycin |
17-DMAG, Hydrochloride Salt, D-3440 ÂüÁ¶ |
| DJM-166 |
PX-866, P-7501 ÂüÁ¶ |
| DJM-2-166 |
PX-866 P-7501 ÂüÁ¶ |
|
17-DMAG, Hydrochloride Salt
ºÐÀÚ·® : 653.21 ; ºÐÀÚ½Ä : C32H48N4O8.HCl
¿ëÇØµµ :Soluble in DMSO; soluble up to about 2 mg/mL in water. |
D-3440 |
250mg, 1g, 2g, 5g, 10g, 25g |
>99% |
[150270-08-9] |
|
Docetaxel
À̸í :[Taxotere] [RP 56976]
ºÐÀÚ·® : 807.88 ; ºÐÀÚ½Ä : C43H53NO14
¿ëÇØµµ :Soluble in DMSO (up to about 200 mg/mL) or ethanol (up to about 100 mg/mL). |
D-1000 |
100mg, 500mg, 1g, 2, 5g, 10g |
>99% |
[114977-28-5] |
|
Doramapimod, Free Base
À̸í :[BIRB 796]
ºÐÀÚ·® : 527.66 ; ºÐÀÚ½Ä : C31H37N5O3
¿ëÇØµµ :Soluble in DMSO. |
D-2744 |
5mg, 25mg, 100mg |
>98% |
[285983-48-4] |
|
Dovitinib, Free Base
À̸í :[CHIR-258] [TKI-258]
ºÐÀÚ·® : 392.43 ; ºÐÀÚ½Ä : C21H21FN6O
¿ëÇØµµ :Soluble in DMSO. |
D-3608 |
10mg, 25mg, 50mg, 100mg, 200mg, 500mg, 1g |
>99% |
[405169-16-6] |
| dPAc |
Prostratin, P-4462 ÂüÁ¶ |
| dPB |
12-Deoxyphorbol 13-Isobutyrate, D-5571 ÂüÁ¶ |
| dPP |
12-Deoxyphorbol 13-Phenylacetate, D-8660 ÂüÁ¶ |
| DQ-2805 |
Irinotecan, Hydrochloride Salt, Trihydrate, I-4122 ÂüÁ¶ |
| Effient |
Prasugrel, Free Base, P-6866 ÂüÁ¶ |
| Efient |
Prasugrel, Free Base, P-6866 ÂüÁ¶ |
| Elactocin |
Leptomycin B, Free Acid, L-6100 ÂüÁ¶ |
| Elidel |
Pimecrolimus, P-6040 ÂüÁ¶ |
| Eloxatin |
Oxaliplatin, O-7111 ÂüÁ¶ |
| Eloxatine |
Oxaliplatin, O-7111 ÂüÁ¶ |
| Elplat |
Oxaliplatin, O-7111 ÂüÁ¶ |
| ENMD-0997 |
(R,S)-Lenalidomide, Free Base, L-5499 ÂüÁ¶ |
Entinostat, Free Base
À̸í :[4',7-Isoflavandiol]
ºÐÀÚ·® : ; ºÐÀÚ½Ä :
¿ëÇØµµ :Soluble in DMSO, methanol or ethanol. |
E-3866 |
25mg, 50mg, 100mg, 200mg, 1g, 2g |
>99% |
|
Enzastaurin, Free Base 
À̸í :
ºÐÀÚ·® : ; ºÐÀÚ½Ä :
¿ëÇØµµ :Soluble in DMSO, methanol or ethanol. |
E-4506 |
100mg, 500mg, 1g, 5g, 10g |
>99% |
|
|
(R,S)-Equol
À̸í :[4',7-Isoflavandiol]
ºÐÀÚ·® : 242.27 ; ºÐÀÚ½Ä : C15H14O3
¿ëÇØµµ :Soluble in DMSO, methanol or ethanol. |
E-5880 |
100mg, 500mg, 1g, 5g, 10g |
>99% |
[531-95-3] |
| Eril |
Fasudil, Monohydrochloride Salt, F-4660; HA-1077, Dihydrochloride Salt, H-2330 ÂüÁ¶ |
|
Erlotinib, Hydrochloride Salt
ºÐÀÚ·® : 429.90 ; ºÐÀÚ½Ä : C22H23N3O4.HCl
¿ëÇØµµ :Soluble in DMSO, methanol or ethanol. |
E-4007 |
1g, 2g, 5g, 10g, 25g, 100g |
>99% |
[183319-69-9] |
|
Everolimus
À̸í :[SDZ-RAD] [Certican] [RAD001]
ºÐÀÚ·® : 958.22 ; ºÐÀÚ½Ä : C53H83NO14
¿ëÇØµµ :Soluble in DMSO at 100 mg/mL; soluble in ethanol at 100 mg/mL; very poorly soluble in water; maximum solubility in plain water is estimated to be about 1-10 ¥ìM; buffers, serum, or other additives may increase or decrease the aqueous solubility. |
E-4040 |
5mg, 25mg, 100mg, 300mg |
>99% |
[159351-69-6] |
| Faridak |
Panobinostat, Free BaseP-3703 ÂüÁ¶ |
| Fasudil |
Fasudil, Monohydrochloride Salt, F-4660; HA-1077, Dihydrochloride Salt, H-2330 ÂüÁ¶ |
|
Fasudil, Monohydrochloride Salt
ºÐÀÚ·® : 327.83 ; ºÐÀÚ½Ä : C14H17N3O2S.HCl0
¿ëÇØµµ :Very soluble in water, up to about 200 mg/mL ; soluble in DMSO up to about 95 mg/mL; not soluble in ethanol; addition of an aqueous solution of this monohydrochloride salt into a buffer solution may significantly alter its solubility. |
F-4660 |
250mg, 500mg, 1g, 2g, 5g, 10g |
>99% |
[105628-07-7] |
|
Fingolimod, Hydrochloride Salt
À̸í :[FTY-720A] [FTY720]
ºÐÀÚ·® : 343.938 ; ºÐÀÚ½Ä : C19H33NO2?HCl
¿ëÇØµµ :Soluble in DMSO . |
F-4633 |
50mg, 100mg, 200mg, 300mg,1g, 2g, 5g, 10g |
>98% |
[162359-56-0] |
|
FK-506
À̸í :[Tacrolimus] [Fujimycin] [Prograf]
ºÐÀÚ·® : 804.02 ; ºÐÀÚ½Ä : C44H69NO12
¿ëÇØµµ :Soluble in DMSO at 100 mg/mL; soluble in ethanol at 100 mg/mL; very poorly soluble in water; maximum solubility in plain water is estimated to be about 10 ¥ìM; buffers, serum, or other additives may increase or decrease the aqueous solubility. |
F-4900 |
50mg, 100mg, 200mg, 500mg, 1g, 2g, 5g |
>98% |
[104987-11-3] |
| FK-520 |
Ascomycin, A-1040 ÂüÁ¶ |
| Foloxatine |
Oxaliplatin, O-7111 ÂüÁ¶ |
|
Forskolin
ºÐÀÚ·® : 410.50 ; ºÐÀÚ½Ä : C22H34O7
¿ëÇØµµ :Soluble in DMSO (5 mg/ml) or ethanol (6 mg/ml). |
F-9929 |
50mg, 100mg, 300mg, 1g, 3 g |
>99% |
[66575-29-9] |
| FR 900520 |
Ascomycin, A-1040 ÂüÁ¶ |
| FR-520 |
Ascomycin, A-1040 ÂüÁ¶ |
| FTY720 |
Fingolimod, Hydrochloride Salt, F-4633 ÂüÁ¶ |
| FTY-720A |
Fingolimod, Hydrochloride Salt, F-4633 ÂüÁ¶ |
| Fujimycin |
FK-506, F-4900 ÂüÁ¶ |
|
Gefitinib, Free Base
À̸í :[ZD-1839] [Iressa]
ºÐÀÚ·® : 446.90 ; ºÐÀÚ½Ä : C22H24ClFN4O3
¿ëÇØµµ :Soluble in DMSO, up to about 100 mg/mL; very poorly soluble in water or ethanol. |
G-4408 |
1g, 2g, 5g, 10g, 25g, 100g |
>99% |
[184475-35-2] |
|
Geldanamycin
À̸í :[Geldanomycin] [U-29135]
ºÐÀÚ·® : 560.64 ; ºÐÀÚ½Ä : C29H40N2O9
¿ëÇØµµ :Soluble in DMSO at 100 mg/mL; see further information below for stability and solubility in other solvents. |
G-4500 |
250mg, 1g, 2g, 5g, 10g, 25g |
>99% |
[30562-34-6] |
| Geldanomycin |
Geldanamycin, G-4500 ÂüÁ¶ |
Gemcitabine, Hydrochloride Salt 
À̸í :[dFdC] [Gamcitabine] [Gemcitera] [Gemsar] [Gemzar] [LY-188011]
ºÐÀÚ·® : ; 299.66 ºÐÀÚ½Ä : C9H11F2N3O4?HCl
¿ëÇØµµ : Soluble in DMSO at 12.5 mg/mL with slight warming; very poorly soluble in ethanol; soluble in water at 25 mg/mL with slight warming; buffers, serum, or other additives may increase or decrease the aqueous solubility. |
G-4177 |
100mg, 300mg, 500mg, 1g, 2g, 5g |
>99% |
[122111-03-9] |
| Gemcitera |
Gemcitabine, Hydrochloride Salt G-4177 ÂüÁ¶ |
| Gemsar |
Gemcitabine, Hydrochloride Salt G-4177 ÂüÁ¶ |
| Gemzar |
Gemcitabine, Hydrochloride Salt G-4177 ÂüÁ¶ |
|
Genistein
À̸í :[4',5,7-Trihydroxyisoflavone]
ºÐÀÚ·® : 270.24 ; ºÐÀÚ½Ä : C15H10O5
¿ëÇØµµ :Soluble in DMSO. |
G-6055 |
1g, 10g, 25g, 100g |
>99% |
[446-72-0] |
|
Genistin
À̸í :[Genistein, 7-O-¥â-D-glucopyranoside]
ºÐÀÚ·® : 432.384 ; ºÐÀÚ½Ä : C21H20O10
¿ëÇØµµ :Soluble in DMSO. |
G-5200 |
25mg, 100mg, 300mg, 1g |
>99% |
[529-59-9] |
| GLD-36 |
17-AAG, A-6880 ÂüÁ¶ |
| Gleevec |
Imatinib, Methanesulfonate Salt, I-5508 ÂüÁ¶ |
| Glivec |
Imatinib, Methanesulfonate Salt, I-5508 ÂüÁ¶ |
|
Glycitein
À̸í :[4',7-Dihydroxy-6-methoxyisoflavone]
ºÐÀÚ·® : 284.26 ; ºÐÀÚ½Ä : C16H12O5
¿ëÇØµµ :Very insoluble (less than 100 ¥ìg/ml) in methanol, ethanol, or water; soluble in DMSO. |
G-1152 |
5mg, 10mg, 25mg, 100mg |
>99% |
[40957-83-3] |
|
Glycitin
À̸í :[Glycitein, 7-O-¥â-D-glucopyranoside]
ºÐÀÚ·® : 446.40 ; ºÐÀÚ½Ä : C22H22O10
¿ëÇØµµ :Soluble in DMSO poorly; insoluble in other solvents. |
G-2822 |
5mg, 10mg, 25mg, 100mg |
>99% |
[40246-10-4] |
| Goe 5549 |
CI-994, Free Base C-2606 ÂüÁ¶ |
| Go 5549 |
CI-994, Free Base C-2606 ÂüÁ¶ |
|
Go 6976
À̸í :[PD 406976] [Go 6976]
ºÐÀÚ·® : 378.43 ; ºÐÀÚ½Ä : C24H18N4O0
¿ëÇØµµ :Soluble in DMSO. |
G-6203 |
1 mg, 5mg |
>99% |
[136194-77-9] |
| GSK 572016 |
Lapatinib, Free Base L-4899 ÂüÁ¶ |
GW2580, Free Base 
À̸í :[cFMS Receptor Tyrosine Kinase Inhibitor] [CSF-1 Receptor Inhibitor]
ºÐÀÚ·® : ; 366.41 ºÐÀÚ½Ä : C20H22N4O3
¿ëÇØµµ : Soluble in DMSO at 40 mg/mL; very poorly soluble in ethanol; very poorly soluble in water; maximum solubility in plain water is estimated to be about 20-100 ¥ìM; buffers, serum, or other additives may increase or decrease the aqueous solubility. |
G-5903 |
100mg, 300mg, 1g, 5g |
>99% |
[870483-87-7] |
| GW-572016 |
Lapatinib, Di-p-Toluenesulfonate Salt, L-4804 ÂüÁ¶ |
| GW-786034 |
Pazopanib, Free Base P-6706 ÂüÁ¶ |
|
H-89, Dihydrochloride Salt
À̸í :[N-[2-(p-Bromocinnamylamino)ethyl]-5-isoquinoline sulfonamide, Di-HCl Salt]
ºÐÀÚ·® : 519.28 ; ºÐÀÚ½Ä : C20H20BrN3O2S.2HCl
¿ëÇØµµ :Soluble in DMSO, water (up to 25 mg/mL; heat to dissolve), or ethanol/water. |
H-5239 |
10 mg, 25mg, 100mg, 300mg |
>99% |
[127243-85-0] |
| HA-1077 |
Fasudil, Monohydrochloride Salt,¹× HA-1077, Dihydrochloride Salt. F-4660 ÂüÁ¶ |
|
HA-1077, Dihydrochloride Salt,
À̸í :[Fasudil, Dihydrochloride Salt] [1-(5-Isoquinolinesulfonyl)homopiperazine, Dihydrochloride Salt] [Eril] [AT-877]
ºÐÀÚ·® : 364.29 ; ºÐÀÚ½Ä : C14H17N3O2S.2HCl
¿ëÇØµµ :Very soluble in water, up to 200 mg/mL or more; soluble in DMSO up to about 10 mg/mL; not soluble in ethanol; addition of an aqueous solution of this dihydrochloride salt into a buffer solution may significantly alter its solubility. |
H-2330 |
250mg, 500mg, 1g, 2g,5g, 10g |
>99% |
[103745-39-7] |
| Halochondrine A |
Okadaic Acid, Free Acid, O-2220 ÂüÁ¶ |
| Halochondrine A, Ammonium Salt |
Okadaic Acid, Ammonium Salt, O-6410 ÂüÁ¶ |
| Halochondrine A, Potassium Salt |
Okadaic Acid, Potassium Salt, O-7519 ÂüÁ¶ |
| Histone Deacetylase Inhibitor I |
Entinostat, Free Base E-3866 ÂüÁ¶ |
| Halochondrine A, Sodium Salt |
Okadaic Acid, Sodium Salt,O-5857 ÂüÁ¶ |
| Imatinib Mesylate |
Imatinib, Methanesulfonate Salt, I-5508 ÂüÁ¶ |
|
Imatinib, Methanesulfonate Salt
À̸í :[Imatinib Mesylate] [Gleevec] [Glivec] [CGP-57148B] [STI-571]
ºÐÀÚ·® : 589.71 ; ºÐÀÚ½Ä : C29H31N7O.CH4SO3
¿ëÇØµµ :Soluble in DMSO at 100 mg/mL; very poorly soluble in ethanol; soluble in water at 200 mg/mL; buffers, serum, or other additives may increase or decrease the aqueous solubility. |
I-5508 |
500mg, 1g, 2g, 5g, 10g, 25g |
>99% |
[220127-57-1] |
| Immunomycin |
Ascomycin, A-1040 ÂüÁ¶ |
|
(-)-Indolactam V
ºÐÀÚ·® : 301.38 ; ºÐÀÚ½Ä : C17H23N3O2
¿ëÇØµµ :Soluble in DMSO or ethanol.ÁÖÀÇ:Weak tumor promoter. Gloves and mask should be worn when using this compound. Care must be taken to avoid contact via all routes of exposure. |
I-1711 |
300ug, 1mg, 5mg |
>99% |
[90365-57-4] |
|
Ingenol
ºÐÀÚ·® : 348.43 ; ºÐÀÚ½Ä : C20H28O5
¿ëÇØµµ :Soluble in DMSO or ethanol. |
I-8560 |
1 mg, 5mg |
>99% |
[30220-46-3] |
|
Ingenol 3-Angelate
À̸í :[PEP005] [3-Ingenyl Angelate] [Ingenyl 3-Angelate] [3-Angeloyl Ingenol] [3-Angelyl Ingenol]
ºÐÀÚ·® : 430.53 ; ºÐÀÚ½Ä : C23H22O10
¿ëÇØµµ :Soluble in DMSO or ethanol.
ÁÖÀÇ:TUMOR PROMOTER. Gloves and mask should be worn when using this compound. Care must be taken to prevent contact through all routes of exposure |
I-5900 |
1 mg, 5 mg |
>99% |
|
|
Ingenol 3-Angelate 20-Acetate
À̸í :[Ingenyl 3-Angelate 20-Acetate] [3-Ingenyl Angelate 20-Acetate]
ºÐÀÚ·® : 472.57; ºÐÀÚ½Ä :C27H36O7
¿ëÇØµµ :Soluble in DMSO or ethanol. ÁÖÀÇ:TUMOR PROMOTER. Gloves and mask should be worn when using this compound. Care must be taken to prevent contact through all routes of exposure |
I-9000 |
1 mg |
>99% |
|
| 3-Ingenyl Angelate |
Ingenol 3-Angelate, I-5900 ÂüÁ¶ |
| Ingenyl 3-Angelate |
Ingenol 3-Angelate, I-5900 ÂüÁ¶ |
| 3-Ingenyl Angelate 20-Acetate |
Ingenol 3-Angelate 20-Acetate, I-9000 ÂüÁ¶ |
| Ingenyl 3-Angelate 20-Acetate |
Ingenol 3-Angelate 20-Acetate, I-9000 ÂüÁ¶ |
|
6'-Iodoresiniferatoxin
ºÐÀÚ·® : ; ºÐÀÚ½Ä :
¿ëÇØµµ : |
I-2000 |
|
|
|
|
Ionomycin, Calcium Salt
ºÐÀÚ·® : 747.07 ; ºÐÀÚ½Ä : C41H70O9.Ca
¿ëÇØµµ :Soluble in DMSO. ÁÖÀÇ:Toxic. |
I-6800 |
5mg, 10mg, 25mg, 100mg |
>99% |
[56092-82-1] |
|
Ionomycin, Free Acid
ºÐÀÚ·® :709.00 ; ºÐÀÚ½Ä : C41H72O9
¿ëÇØµµ :Soluble in DMSO, methanol or ethanol. ÁÖÀÇ:Toxic. |
I-5700 |
1 mg, 5mg, 10mg, 25mg |
>99% |
[56092-81-0] |
| Iressa |
Gefitinib, Free Base, G-4408 ÂüÁ¶ |
|
Irinotecan, Hydrochloride Salt, Trihydrate
À̸í :[Camptosar] [Topotecin] [Campto] [Camptothecin 11] [CPT-11] [U-101440E] [DQ-2805]
ºÐÀÚ·® :677.18 ; ºÐÀÚ½Ä : C33H38N4O6.HCl.3H2O
¿ëÇØµµ :Soluble in DMSO at 100 mg/mL; very poorly soluble in ethanol; soluble in water at 25 mg/mL; buffers, serum, or other additives may increase or decrease the aqueous solubility.> |
I-4122 |
100mg, 250mg, 1g, 2g |
>99% |
[136572-09-3] |
| 6'-IRTX |
6'-Iodoresiniferatoxin I-2000 ÂüÁ¶ |
| 4',7-Isoflavandiol |
Equol, E-5880 ÂüÁ¶ |
| JNK Inhibitor II |
SP600125, S-7979 ÂüÁ¶ |
|
K-252a
À̸í : [K252a]
ºÐÀÚ·® : 467.47 ; ºÐÀÚ½Ä : C27H21N3O5
¿ëÇØµµ :Soluble in DMSO at 100 mg/mL; poorly soluble in ethanol. |
K-2151 |
1 mg, 5mg, 25mg |
>99% |
[97161-97-2] |
|
K-252c
À̸í : [Staurosporine Aglycone] [Staurosporinone] [K252c] [K 252c]
ºÐÀÚ·® : 311.34 ; ºÐÀÚ½Ä : C20H13N3O
¿ëÇØµµ :Soluble in DMSO, methanol or ethanol. |
K-9609 |
1 mg, 5mg |
>99% |
[85753-43-1] |
| K252a |
K-252a, K-2151 ÂüÁ¶ |
| K252c |
K-252c, K-9609 ÂüÁ¶ |
| KOS-953 |
17-AAG, A-6880 ÂüÁ¶ |
| KT-5555 |
Lestaurtinib, L-6307 ÂüÁ¶ |
| KY 12420 |
Wortmannin, W-2990 ÂüÁ¶ |
| L 683590 |
Ascomycin, A-1040 ÂüÁ¶ |
|
Lapatinib, Di-p-Toluenesulfonate Salt,
À̸í : [Lapatinib Ditosylate] [Tykerb] [GW-572016] [Tyverb]
ºÐÀÚ·® : 925.46 ; ºÐÀÚ½Ä : C29H26ClFN4O4S.2C7H8O3S
¿ëÇØµµ :Soluble in DMSO at 200 mg/mL; very poorly soluble in ethanol; very poorly soluble in water; maximum solubility in plain water is estimated to be about 1-10 ¥ìM; buffers, serum, or other additives may increase or decrease the aqueous solubility. |
L-4804 |
100mg, 200mg, 300mg, 500mg, 1g, 2g, 5g, 10g |
>99% |
[388082-78-8] |
Lapatinib, Free Base 
À̸í :[dFdC] [Gamcitabine] [Gemcitera] [Gemsar] [Gemzar] [LY-188011]
ºÐÀÚ·® : ; 581.06 ºÐÀÚ½Ä : C29H26ClFN4O4S
¿ëÇØµµ : Soluble in DMSO at 200 mg/mL; very poorly soluble in ethanol; very poorly soluble in water; maximum solubility in plain water is estimated to be about 1-10 ¥ìM; buffers, serum, or other additives may increase or decrease the aqueous solubility. |
L-4899 |
100mg, 200mg, 300mg, 500mg, 1g, 2g, 5g, 10g |
>99% |
[231277-92-2] |
| Latisse |
Bimatoprost B-2777 ÂüÁ¶ |
| LBH-589 |
Panobinostat, Free Base P-3703 ÂüÁ¶ |
| LCP-Siro |
Rapamycin, R-5000 ÂüÁ¶ |
(R,S)-Lenalidomide, Free Base 
À̸í :[CC-5013] [CDC-501] [ENMD-0997] [Revamid] [Revimid] [Revlimid]
ºÐÀÚ·® : ; 259.26 ºÐÀÚ½Ä : C13H13N3O3
¿ëÇØµµ : Soluble in DMSO at 100 mg/mL; very poorly soluble in ethanol; very poorly soluble in water; maximum solubility in plain water is estimated to be about 20-100 ¥ìM; buffers, serum, or other additives may increase or decrease the aqueous solubility |
L-5499 |
200mg, 500mg, 1g, 2g, 5g, 10g |
>99% |
[191732-72-6] |
|
Leptomycin B, Free Acid
À̸í : [LMB] [Elactocin] [Mantuamycin] [CI-940] [CL-1957A] [PD-114720] [ATS 1287B]
ºÐÀÚ·® : 540.73 ; ºÐÀÚ½Ä : C33H48O6
¿ëÇØµµ :Soluble in methanol or ethanol. |
L-6100 |
100ug, 500ug, 1mg |
>99% |
[87081-35-4] |
|
Lestaurtinib
À̸í : [CEP-701] [KT-5555]
ºÐÀÚ·® : 439.46 ; ºÐÀÚ½Ä : C26H21N3O4
¿ëÇØµµ :Soluble in DMSO at 100 mg/mL; soluble in ethanol at 20 mg/mL; very poorly soluble in water; maximum solubility in plain water is estimated to be about 10 ¥ìM; buffers, serum, or other additives may increase or decrease the aqueous solubility. |
L-6307 |
1 mg, 5mg, 25mg, 100mg, 300mg |
>99% |
[111358-88-4] |
| LG 1069 |
Bexarotene, Free Acid, B-2422 ÂüÁ¶ |
| LG100069 |
Bexarotene, Free Acid, B-2422 ÂüÁ¶ |
| LGD-1069 |
Bexarotene, Free Acid, B-2422 ÂüÁ¶ |
| Lilly 68618 |
Mycophenolic Acid, Free Acid M-7800 ÂüÁ¶ |
| LMB |
Leptomycin B, Free Acid, L-6100 ÂüÁ¶ |
| Lumigan |
Bimatoprost B-2777 ÂüÁ¶ |
| LY-188011 |
Gemcitabine, Hydrochloride Salt G-4177 ÂüÁ¶ |
| LY-231514 |
Gemcitabine, Hydrochloride Salt G-4177 ÂüÁ¶ |
|
LY 294002
À̸í : [2-(4-Morpholino)-8-phenyl-4H-1-benzopyran-4-one]
ºÐÀÚ·® : 307.34 ; ºÐÀÚ½Ä : C19H17NO3
¿ëÇØµµ :Soluble in DMSO or ethanol. |
L-7962 |
5mg, 10mg, 25mg, 50mg, 100mg, 200mg, 300mg |
>99% |
[154447-36-6] |
|
6"-O-Malonyldaidzin, Free Acid
ºÐÀÚ·® : 502.42 ; ºÐÀÚ½Ä : C24H22O12
¿ëÇØµµ :Soluble in DMSO, methanol, ethanol, or mixtures of acetonitrile/water. |
M-6730 |
1 mg, 5mg, 10mg, 25mg |
>98% |
|
|
6"-O-Malonylgenistin, Free Acid
ºÐÀÚ·® : 518.42 ; ºÐÀÚ½Ä : C24H22O13
¿ëÇØµµ :Soluble in DMSO, methanol, ethanol, or mixtures of acetonitrile/water. |
M-8090 |
1 mg, 5mg, 10mg, 25mg |
>98% |
|
|
6"-O-Malonylglycitin, Free Acid
ºÐÀÚ·® : 532.45 ; ºÐÀÚ½Ä : C25H24O13
¿ëÇØµµ :Soluble in DMSO, methanol, ethanol, or mixtures of acetonitrile/water. |
M-4620 |
1 mg, 5mg, 10mg, 25mg |
>98% |
|
| Mantuamycin |
Leptomycin B, Free Acid, L-6100 ÂüÁ¶ |
| Masatinib |
Masitinib, Free Base M-7007 ÂüÁ¶ |
|
Masitinib, Free Base
À̸í : [AB-1010] [Masatinib] 8
ºÐÀÚ·® : 498.648; ºÐÀÚ½Ä : C28H30N6OS
¿ëÇØµµ :Soluble in DMSO. |
M-7007 |
25mg, 50mg, 100mg, 200mg, 1g |
>99% |
[790299-79-5] |
| Melbex |
Mycophenolic Acid, Free Acid M-7800 ÂüÁ¶ |
|
4-O-Methylphorbol 12-Myristate 13-Acetate
À̸í : [Phorbol 12-Myristate 13-Acetate 4-O-Methyl Ether]
ºÐÀÚ·® : 630.85; ºÐÀÚ½Ä : C37H58O8
¿ëÇØµµ :Soluble in DMSO, ethanol, or acetone. ÁÖÀÇ:Weak tumor promoter. |
M-2550 |
1 mg, 5mg |
>99% |
[57716-89-9] |
| MG-0103 |
Mocetinostat, Free Base, M-2433 ÂüÁ¶ |
| MG-341 |
Bortezomib, B-1408 ÂüÁ¶ |
| MGCD0103 |
Mocetinostat, Free Base, M-2433 ÂüÁ¶ |
| Midostaurin |
PKC412, P-7600 ÂüÁ¶ |
| MK-0457 |
Tozasertib, Free Base, T-2304 ÂüÁ¶ |
| MK-0476 |
Montelukast, Sodium Salt M-4966 ÂüÁ¶ |
| MK-8669 |
Ridaforolimus R-7040 ÂüÁ¶ |
| MLN518 |
Tandutinib, Free Base T-7802 ÂüÁ¶ |
Mocetinostat, Free Base
À̸í : [MG-0103] [MGCD0103]
ºÐÀÚ·® : 396.44 ; ºÐÀÚ½Ä : C23H20N6O
¿ëÇØµµ : Soluble in DMSO. |
M-2433 |
10mg, 50mg, 200mg 1g |
>99% |
[726169-73-9] |
| MPA |
Mycophenolic Acid, Free Acid M-7800 ÂüÁ¶ |
| MS-27-275 |
Entinostat, Free Base E-3866 ÂüÁ¶ |
| MS-275 |
Entinostat, Free Base E-3866 ÂüÁ¶ |
| MS 275-27 |
Entinostat, Free Base E-3866 ÂüÁ¶ |
| MTA |
Pemetrexed, Disodium Salt, Heptahydrate P-7177ÂüÁ¶ |
|
Mubritinib, Free Base
À̸í : [TAK-165]
ºÐÀÚ·® : 468.473 ; ºÐÀÚ½Ä : C25H23F3N4O2
¿ëÇØµµ : Soluble in DMSO. |
M-5602 |
10mg, 25mg, 50mg, 100mg, 200mg 500mg |
>99% |
[366017-09-6] |
|
Mycophenolic Acid, Free Acid,
À̸í : [MPA] [Melbex] [Myfortic] [CellCept] [Lilly 68618]
ºÐÀÚ·® : 320.343 ; ºÐÀÚ½Ä : C17H20O6
¿ëÇØµµ : Soluble in DMSO at 200 mg/mL; soluble in ethanol at 30 mg/mL; very poorly soluble in water; maximum solubility in plain water is estimated to be about 10-100 ¥ìM; solubility is higher in pH7 buffer; buffers, serum, or other additives may increase or decrease the aqueous solubility. |
M-7800 |
500mg, 1g, 5g, 10g |
>99% |
[24280-93-1] |
| Myfortic |
Mycophenolic Acid, Free Acid M-7800 ÂüÁ¶ |
| Nectrolide |
Brefeldin A, B-8500 ÂüÁ¶ |
| Nexavar |
Sorafenib, p-Toluenesulfonate Salt, S-8502 ¹× Sorafenib, Free Base, S-8599 ÂüÁ¶ |
|
Nilotinib, Free Base
À̸í : [AMN-107] [Tasigna]
ºÐÀÚ·® : 529.52 ; ºÐÀÚ½Ä : C28H22F3N7O
¿ëÇØµµ :Soluble in DMSO, up to about 50 mg/mL; not soluble in ethanol or water. |
N-8207 |
25mg, 100mg, 300mg, 500mg, 1g, 2g, 5g |
>99% |
[641571-10-0] |
|
NVP-BEZ235, Free Base
À̸í : [BEZ235]
ºÐÀÚ·® : 469.54 ; ºÐÀÚ½Ä : C30H23N5O
¿ëÇØµµ :Soluble in DMSO. |
N-4288 |
10mg, 25mg, 50mg, 100mg, 200mg, 1 g |
>99% |
[915019-65-7] |
| NVP-LBH-589 |
Panobinostat, Free Base, P-3703 ÂüÁ¶ |
|
Okadaic Acid, Ammonium Salt
À̸í : [Halochondrine A, Ammonium Salt]
ºÐÀÚ·® : 822.03 ; ºÐÀÚ½Ä : C44H67O13.NH4
¿ëÇØµµ :Soluble in DMSO, methanol or ethanol. ÁÖÀÇ:Highly irritant to skin and mucous membranes. SPECIAL HAZARD: TUMOR PROMOTER. Gloves and mask should be worn when using this compound. Care must be taken to prevent contact through all routes of exposure. |
O-6410 |
50ug, 100ug, 300ug, 1mg, 2mg, 5mg |
>98% |
[155716-06-6] |
|
Okadaic Acid, Free Acid
À̸í : [Halochondrine A]
ºÐÀÚ·® : 805.00 ; ºÐÀÚ½Ä : C44H68O13
¿ëÇØµµ :Soluble in DMSO or ethanol. ÁÖÀÇ:Highly irritant to skin and mucous membranes. SPECIAL HAZARD: TUMOR PROMOTER. Gloves and mask should be worn when using this compound. Care must be taken to prevent contact through all routes of exposure. |
O-2220 |
50ug, 100ug, 300ug, 1mg, 2mg, 5mg |
>99% |
[78111-17-8] |
|
Okadaic Acid, Potassium Salt
À̸í : [Halochondrine A, Potassium Salt]
ºÐÀÚ·® : 843.09 ; ºÐÀÚ½Ä : C44H67O13.K
¿ëÇØµµ :Soluble in DMSO or ethanol. ÁÖÀÇ:Highly irritant to skin and mucous membranes. SPECIAL HAZARD: TUMOR PROMOTER. Gloves and mask should be worn when using this compound. Care must be taken to prevent contact through all routes of exposure. |
O-7519 |
50ug, 100ug, 300ug, 1mg, 2mg, 5mg |
>98% |
[155751-72-7] |
|
Okadaic Acid, Sodium Salt
À̸í : [Halochondrine A, Sodium Salt]
ºÐÀÚ·® : 826.98 ; ºÐÀÚ½Ä : C44H67O13.Na
¿ëÇØµµ :Soluble in DMSO, methanol or ethanol. ÁÖÀÇ:Highly irritant to skin and mucous membranes. SPECIAL HAZARD: TUMOR PROMOTER. Gloves and mask should be worn when using this compound. Care must be taken to prevent contact through all routes of exposure. |
O-5857 |
50ug, 100ug, 300ug, 1mg, 2mg, 5mg |
>98% |
[209266-80-8] |
| Onsenal |
Celecoxib, C-1502 ÂüÁ¶ |
| OSI-774 |
Erlotinib, Hydrochloride Salt, E-4007 ÂüÁ¶ |
|
OSU-03012, Hydrochloride Salt
À̸í : [OSU03012]
ºÐÀÚ·® : 496.91 ; ºÐÀÚ½Ä : C26H19F3N4O.HCl
¿ëÇØµµ :Soluble in DMSO. |
O-5679 |
5mg, 25mg, 100mg |
>98% |
[742112-33-0] |
| OSU03012 |
OSU-03012, Hydrochloride Salt, O-5679 ÂüÁ¶ |
| Oxalato(1R,2R-cyclohexanediamine)platinum(II) |
Oxaliplatin, O-7111 ÂüÁ¶ |
| Oxalatoplatin |
Oxaliplatin, O-7111 ÂüÁ¶ |
| Oxalatoplatinum |
Oxaliplatin, O-7111 ÂüÁ¶ |
|
Oxaliplatin
À̸í : [Foloxatine] [Transplatin] [Eloxatin] [Eloxatine] [Elplat] [RP 54780] [Dacplat] [Oxalato(1R,2R-cyclohexanediamine)platinum(II)] [Oxalatoplatin] [Oxalatoplatinum]
ºÐÀÚ·® : 397.29 ; ºÐÀÚ½Ä : C8H14N2O4Pt
¿ëÇØµµ :Soluble in water at 4 mg/mL and DMSO at 20 mg/mL; very slightly soluble in methanol; insoluble in ethanol. |
O-7111 |
300mg, 1g, 2g |
>99% |
[61825-94-3][63121-00-6] |
|
Paclitaxel
À̸í : [Taxol]
ºÐÀÚ·® : 853.91; ºÐÀÚ½Ä : C47H51NO14
¿ëÇØµµ :Soluble in DMSO (up to about 200 mg/mL) or ethanol (up to about 40 mg/mL). |
P-9600 |
100mg, 500mg, 1g, 2g, 5g, 10g |
>99.5% |
[33069-62-4] |
Panobinostat, Free Base 
À̸í :[Faridak] [LBH-589] [NVP-LBH-589]
ºÐÀÚ·® : ; 349.43 ºÐÀÚ½Ä : C21H23N3O2
¿ëÇØµµ : Soluble in DMSO. |
P-3703 |
5mg, 25mg, 50mg, 100mg, 300mg, 1g |
>99% |
[404950-80-7] |
|
Pazopanib, Free base
À̸í : [GW-786034] [Armala]
ºÐÀÚ·® : 437.52 ºÐÀÚ½Ä : C21H23N7O2S
CAS No. :[444731-52-6]
¿ëÇØµµ :Soluble in DMSO |
P-6706 |
10mg, 25mg, 50mg, 100mg, 200mg, 500mg, 1g |
>99.0% |
|
|
PD 98059
À̸í : [2'-Amino-3'-methoxyflavone] [PD98059] [PD-98059]
ºÐÀÚ·® : 267.28; ºÐÀÚ½Ä : C16H13NO3
¿ëÇØµµ : Soluble in DMSO. |
P-4313 |
5mg, 10mg, 25mg, 50mg, 100mg, 200mg, 300mg, 1g |
>99% |
[167869-21-8] |
| PD 114720 |
Leptomycin B, Free Acid, L-6100 ÂüÁ¶ |
| PD 123654 |
CI-994, Free Base C-2606 ÂüÁ¶ |
| PD 183805 |
Canertinib, Dihydrochloride Salt C-1201 ÂüÁ¶ |
| PD 406976 |
Go 6976, G-6203 ÂüÁ¶ |
| PDA |
Phorbol 12,13-Diacetate, P-5005 ÂüÁ¶ |
| 4¥á-PDA |
4¥á-Phorbol 12,13-Diacetate, P-1571 ÂüÁ¶ |
| PDBu |
Phorbol 12,13-Dibutyrate, P-4833 ÂüÁ¶ |
| 4¥á-PDBu |
4¥á-Phorbol 12,13-Dibutyrate, P-4678 ÂüÁ¶ |
| PDBz |
Phorbol 12,13-Dibenzoate, P-3106 ÂüÁ¶ |
| PDD |
Phorbol 12,13-Didecanoate, P-1925 ÂüÁ¶ |
| 4¥á-PDD |
4¥á-Phorbol 12,13-Didecanoate, P-2170 ÂüÁ¶ |
| PDH |
Phorbol 12,13-Dihexanoate, P-3814 ÂüÁ¶ |
Pemetrexed, Disodium Salt, Heptahydrate 
À̸í : [Alimta] [LY-231514] [MTA] [Rolazar] [Tifolar]
ºÐÀÚ·® : ; 597.48ºÐÀÚ½Ä : C20H19N5Na2O6?7H2O
¿ëÇØµµ : Very poorly soluble in DMSO; very poorly soluble in ethanol; soluble in water at 100 mg/mL; buffers, serum, or other additives may increase or decrease the aqueous solubility. |
P-7177 |
250mg, 500mg, 1g, 2g, 5g, 10g |
>99% |
[357166-29-1] |
| PEP005 |
Ingenol 3-Angelate, I-5900 ÂüÁ¶ |
| PHA-290940AD |
Sunitinib, Malate Salt, S-8803 , S-8877 ÂüÁ¶ |
|
Phorbol
ºÐÀÚ·® : 364.43 ; ºÐÀÚ½Ä : C20H28O6
¿ëÇØµµ :Soluble in DMSO or ethanol. |
P-1010 |
1 mg, 5mg |
>99% |
[17673-25-5] |
|
Phorbol 13-Acetate
À̸í : [Phorbol 13-Monoacetate]
ºÐÀÚ·® : 406.47; ºÐÀÚ½Ä : C22H30O7
¿ëÇØµµ :Soluble in DMSO or ethanol. |
P-4227 |
1 mg, 5mg |
>99% |
[32752-29-7] |
|
Phorbol 13-Decanoate
À̸í :
ºÐÀÚ·® : 518.68 ; ºÐÀÚ½Ä : C30H46O7
¿ëÇØµµ :Soluble in DMSO, methanol or ethanol. ÁÖÀÇ:Highly irritant to skin and mucous membranes. SPECIAL HAZARD: TUMOR PROMOTER. Gloves and mask should be worn when using this compound. Care must be taken to prevent contact through all routes of exposure. |
P-7350 |
1 mg, 5mg |
>99% |
[123597-59-1] |
|
Phorbol 12,13-Diacetate
À̸í : [PDA]
ºÐÀÚ·® : 448.51 ; ºÐÀÚ½Ä : C24H32O8
¿ëÇØµµ :Soluble in DMSO or ethanol. |
P-5005 |
1 mg, 5mg |
>99% |
[24928-15-2] |
|
4¥á-Phorbol 12,13-Diacetate
À̸í : [4¥á-PDA]
ºÐÀÚ·® : 448.51; ºÐÀÚ½Ä : C24H32O8
¿ëÇØµµ :Soluble in DMSO or ethanol |
P-1571 |
1 mg, 5mg |
>99% |
[56144-62-8] |
|
Phorbol 12,13-Dibenzoate
À̸í : [PDBz]
ºÐÀÚ·® : 572.64 ; ºÐÀÚ½Ä : C34H36O8
¿ëÇØµµ :Soluble in DMSO, methanol or ethanol. ÁÖÀÇ:Highly irritant to skin and mucous membranes. SPECIAL HAZARD: TUMOR PROMOTER. Gloves and mask should be worn when using this compound. Care must be taken to prevent contact through all routes of exposure. |
P-3106 |
1 mg, 5mg |
>99% |
[25405-85-0] |
|
Phorbol 12,13-Dibutyrate
À̸í : [PDBu]
ºÐÀÚ·® : 504.61 ; ºÐÀÚ½Ä : C28H40O8
¿ëÇØµµ :Soluble in DMSO or ethanol. ÁÖÀÇ:Highly irritant to skin and mucous membranes. SPECIAL HAZARD: TUMOR PROMOTER. Gloves and mask should be worn when using this compound. Care must be taken to prevent contact through all routes of exposure. |
P-4833 |
1 mg, 5mg, 10mg |
>99% |
[37558-16-0] |
|
4¥á-Phorbol 12,13-Dibutyrate
À̸í :
ºÐÀÚ·® : ; ºÐÀÚ½Ä :
¿ëÇØµµ : |
P-4678 |
|
|
|
|
Phorbol 12,13-Didecanoate
À̸í : [PDD]
ºÐÀÚ·® : 672.93; ºÐÀÚ½Ä : C40H64O8
¿ëÇØµµ :Soluble in DMSO, methanol or ethanol. ÁÖÀÇ:Highly irritant to skin and mucous membranes. SPECIAL HAZARD: TUMOR PROMOTER. Gloves and mask should be worn when using this compound. Care must be taken to prevent contact through all routes of exposure. |
P-1925 |
1 mg, 5mg |
>99% |
[24928-17-4] |
|
4¥á-Phorbol 12,13-Didecanoate
À̸í : [4¥á-PDD]
ºÐÀÚ·® : 672.93; ºÐÀÚ½Ä : C40H64O8
¿ëÇØµµ :Soluble in DMSO or ethanol. |
P-2170 |
1 mg, 5mg, 10mg, 25mg |
>99% |
[27536-56-7] |
|
Phorbol 12,13-Dihexanoate
À̸í : [PDH]
ºÐÀÚ·® : 560.72 ; ºÐÀÚ½Ä : C32H48O8
¿ëÇØµµ :Soluble in DMSO or ethanol. ÁÖÀÇ:Highly irritant to skin and mucous membranes. SPECIAL HAZARD: TUMOR PROMOTER. Gloves and mask should be worn when using this compound. Care must be taken to prevent contact through all routes of exposure. |
P-3814 |
1 mg, 5mg |
>99% |
[37558-17-1] |
| Phorbol 13-Monoacetate |
Phorbol 13-Acetate, P-4227 ÂüÁ¶ |
|
Phorbol 12-Myristate 13-Acetate
À̸í : [PMA] [TPA] [Cocarcinogen A1] [12-O-Tetradecanoyl-phorbol 13-Acetate]
ºÐÀÚ·® : 616.83; ºÐÀÚ½Ä : C36H56O8
¿ëÇØµµ :Soluble in DMSO or ethanol. ÁÖÀÇ:Highly irritant to skin and mucous membranes. SPECIAL HAZARD: TUMOR PROMOTER. Gloves and mask should be worn when using this compound. Care must be taken to prevent contact through all routes of exposure. |
P-1680 |
1 mg, 5mg, 10mg, 25mg , 100mg |
>99.5% |
[16561-29-8] |
| Phorbol 12-Myristate 13-Acetate 4-O-Methyl Ether |
4-O-Methylphorbol 12-Myristate 13-Acetate, BM-2550 ÂüÁ¶ |
|
4¥á-Phorbol 12-Myristate 13-Acetate
À̸í : [4¥á-PMA] [4¥á-TPA] [4¥á-12-O-Tetradecanoylphorbol 13-Acetate]
ºÐÀÚ·® : 616.83 ; ºÐÀÚ½Ä : C36H56O8
¿ëÇØµµ :Soluble in DMSO or ethanol. |
P-8880 |
1 mg, 5mg, 10mg, 25mg |
>99% |
[63597-44-4] |
|
Pimecrolimus
À̸í : [Elidel] [SDZ-ASM-981]
ºÐÀÚ·® : 810.45 ; ºÐÀÚ½Ä : C43H68ClNO11
¿ëÇØµµ :Soluble in DMSO and ethanol, up to about 25 mg/mL. |
P-6040 |
5mg, 10mg,25mg, 50mg, 100mg, 200mg, 300mg, |
>99% |
[137071-32-0] |
Pemetrexed, Disodium Salt, Heptahydrate 
À̸í :[Alimta] [LY-231514] [MTA] [Rolazar] [Tifolar]
ºÐÀÚ·® : ; 597.48 ºÐÀÚ½Ä : C20H19N5Na2O6?7H2O
¿ëÇØµµ : Very poorly soluble in DMSO; very poorly soluble in ethanol; soluble in water at 100 mg/mL; buffers, serum, or other additives may increase or decrease the aqueous solubility. |
P-7177 |
250mg, 500mg, 1g, 2g, 5g, 10g |
>99% |
[357166-29-1] |
|
PKC412
À̸í : [CGP41251] [4'-N-Benzoyl Staurosporine] [Midostaurin]
ºÐÀÚ·® : 570.64; ºÐÀÚ½Ä : C35H30N4O4
¿ëÇØµµ :Soluble in DMSO. |
P-7600 |
1 mg, 5mg, 10mg, 25mg, 100mg |
>99% |
[120685-11-2] |
| PMA |
Phorbol 12-Myristate 13-Acetate, P-1680 ÂüÁ¶ |
| 4¥á-PMA |
4¥á-Phorbol 12-Myristate 13-Acetate,P-8880 ÂüÁ¶ |
| PNU-290940AD |
Sunitinib, Malate Salt, S-8803, S-8877 ÂüÁ¶ |
Phorbol 13-Decanoate
À̸í :
ºÐÀÚ·® : ; 518.68ºÐÀÚ½Ä : C30H46O7
¿ëÇØµµ : Soluble in DMSO or ethanol. |
P-7350 |
1mg, 5mg |
>99% |
[123597-59-1] |
Prasugrel, Free Base 
À̸í :[CS-747] [Effient] [Efient] [LY-640315]
ºÐÀÚ·® : ; 373.44 ºÐÀÚ½Ä : C20H20FNO3S
¿ëÇØµµ : Soluble in DMSO at 25 mg/mL with slight warming; soluble in ethanol at 5 mg/mL with slight warming; very poorly soluble in water; maximum solubility in plain water is estimated to be about 20-50 ¥ìM; buffers, serum, or other additives may increase or decrease the aqueous solubility. |
P-6866 |
100mg, 300mg, 1g, 2g, 5g |
>99% |
[150322-43-3] |
| Prograf |
FK-506 F-4900 ÂüÁ¶ |
|
PPAHV
À̸í : [Phorbol 12-Phenylacetate 13-Acetate 20-Homovanillate]
ºÐÀÚ·® : 688.76 ; ºÐÀÚ½Ä : C39H44O11
¿ëÇØµµ :Soluble in DMSO or ethanol. ÁÖÀÇ:Highly irritant to skin and mucous membranes. SPECIAL HAZARD: TUMOR PROMOTER. Gloves and mask should be worn when using this compound. Care must be taken to prevent contact through all routes of exposure. |
P-6388 |
1 mg, 5mg |
>99% |
[175796-50-6] |
| Prograf |
FK-506, F-4900 ÂüÁ¶ |
| Prostamide |
Bimatoprost B-2777 ÂüÁ¶ |
|
Prostratin
À̸í : [12-Deoxyphorbol 13-Acetate] [dPAc]
ºÐÀÚ·® : 390.47 ; ºÐÀÚ½Ä : C22H30O6
¿ëÇØµµ :Soluble in DMSO or ethanol. |
P-4462 |
1 mg, 5mg |
>99% |
[60857-08-1] |
| PS-341 |
Bortezomib, B-1408 ÂüÁ¶ |
| PTK 787 |
Vatalanib, Dihydrochloride Salt, V-8303 ÂüÁ¶ |
PX-866
À̸í :[DJM-166] [DJM-2-166]
ºÐÀÚ·® : ; 525.59 ºÐÀÚ½Ä : C29H35NO8
¿ëÇØµµ : Soluble in DMSO |
P-7501 |
5mg, 10mg, 25mg, 100mg, 300mg |
>99% |
[502632-66-8] |
| 1,9-Pyrazoloanthrone |
SP600125, S-7979 ÂüÁ¶ |
| RAD001 |
Everolimus, E-4040 ÂüÁ¶ |
Ramatroban, Free Acid
À̸í :[Baynas] [BAY u3405]
ºÐÀÚ·® : ; 416.47ºÐÀÚ½Ä : C21H21FN2O4S
¿ëÇØµµ : Soluble in DMSO. |
P-7040 |
10mg, 25mg, 50mg, 100mg, 300mg, |
>99% |
[116649-85-5] |
| Ramihyphin A |
Cyclosporin A, C-6000 ÂüÁ¶ |
| RAPA |
Rapamycin, R-5000 ÂüÁ¶ |
| Rapamune |
Rapamycin, R-5000 ÂüÁ¶ |
|
Rapamycin
À̸í : [RAPA] [Rapamune] [Sirolimus] [AY-22989] [LCP-Siro] [SILA 9268A]
ºÐÀÚ·® : 914.17 ; ºÐÀÚ½Ä : C51H79NO13
¿ëÇØµµ :Soluble in DMSO, methanol or ethanol. |
R-5000 |
50mg, 100mg, 200mg, 300mg, 500mg, 1g, 2g, 5g 10g |
>99% |
[53123-88-9] |
|
Resiniferatoxin
À̸í : [RTX]
ºÐÀÚ·® : 628.71; ºÐÀÚ½Ä : C37H40O9
¿ëÇØµµ :Soluble in DMSO or ethanol. ÁÖÀÇ:Highly irritant to skin and mucous membranes. SPECIAL HAZARD: TUMOR PROMOTER. Gloves and mask should be worn when using this compound. Care must be taken to prevent contact through all routes of exposure. |
R-6712 |
1 mg, 5mg, 10mg, 25mg, |
>99% |
[57444-62-9] |
|
Resiniferonol 9,13,14-Orthophenylacetate
À̸í : [ROPA]
ºÐÀÚ·® : 464.55 ; ºÐÀÚ½Ä : C28H32O6
¿ëÇØµµ :Soluble in DMSO or ethanol. ÁÖÀÇ:Highly irritant to skin and mucous membranes. SPECIAL HAZARD: TUMOR PROMOTER. Gloves and mask should be worn when using this compound. Care must be taken to prevent contact through all routes of exposure. |
R-8765 |
1 mg, 5mg, 10mg, 25mg, 100mg |
>99% |
[57852-42-3] |
| Revamid |
(R,S)-Lenalidomide, Free Base, L-5499 ÂüÁ¶ |
| Revimid |
(R,S)-Lenalidomide, Free Base, L-5499 ÂüÁ¶ |
| Revlimid |
(R,S)-Lenalidomide, Free Base, L-5499 ÂüÁ¶ |
Ridaforolimus 
À̸í :[9CI] [AP 23573] [Deforolimus] [MK-8669]
ºÐÀÚ·® : ; 990.21 ºÐÀÚ½Ä : C53H84NO14P
¿ëÇØµµ : Soluble in DMSO. |
P-7040 |
5mg, 10mg, 25mg, 50mg, 200mg, 1g |
>99% |
[572924-54-0] |
Rivaroxaban 
À̸í :[BAY-59-7939] [D07086] [Xarelto]
ºÐÀÚ·® : ; 435.88 ºÐÀÚ½Ä : C19H18ClN3O5S
¿ëÇØµµ : Soluble in DMSO at 12.5 mg/mL with slight warming; very poorly soluble in ethanol; very poorly soluble in water; maximum solubility in plain water is estimated to be about 20-50 ¥ìM; buffers, serum, or other additives may increase or decrease the aqueous solubility. |
P-7199 |
10mg, 20mg, 50mg, 200mg, 1g |
>99% |
[366789-02-8] |
| Ro 09-1978 |
Capecitabine, C-2799 ÂüÁ¶ |
| Rolazar |
Pemetrexed, Disodium Salt, Heptahydrate P-7177 ÂüÁ¶ |
| ROPA |
Resiniferonol 9,13,14-Orthophenylacetate, R-8765 ÂüÁ¶ |
|
Roscovitine, Free Base
À̸í : [CYC202] [Seliciclib] [6-Benzylamino-2[(R)-(1'-ethyl-2'-hydroxyethylamino)]-9-isopropylpurine]
ºÐÀÚ·® : 354.45 ; ºÐÀÚ½Ä : C19H26N6O
¿ëÇØµµ :Prepare initial stock solutions in DMSO (soluble at 200 mg/mL) or ethanol (soluble at 200 mg/mL) for in vitro use; solubility in water is low. |
R-1234 |
5mg, 10mg, 25mg, 100mg, 200mg, 300mg, 1g |
>99% |
[186692-46-6] |
| RP 54780 |
Oxaliplatin, O-7111 ÂüÁ¶ |
| RP 56976 |
Docetaxel, D-1000 ÂüÁ¶ |
| RTX |
Resiniferatoxin, R-6712 ÂüÁ¶ |
| SAHA |
Vorinostat, V-8477 ÂüÁ¶ |
| SAPK Inhibitor II |
SP600125, S-7979 ÂüÁ¶ |
Saracatinib, Free Base 
À̸í :[AZD-0530]
ºÐÀÚ·® : ; 542.039 ºÐÀÚ½Ä : C27H32ClN5O5P
¿ëÇØµµ : Soluble in DMSO. |
S-8906 |
10mg, 25mg, 50mg, 100mg, 200mg, 1g |
>99% |
[379231-04-6] |
|
SB 202190, Free Base
À̸í : [FHPI] [4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1H-imidazole]
ºÐÀÚ·® : 331.34 ; ºÐÀÚ½Ä : C20H14FN3O
¿ëÇØµµ :Soluble in DMSO. |
S-1700 |
10mg, 25mg, 50mg, 100mg, 200mg, 500mg, 1g,
|
>99% |
[152121-30-7] |
|
SB 203580, Free Base
À̸í : [4-(4-Fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)1H-imidazole]
ºÐÀÚ·® : 377.43 ; ºÐÀÚ½Ä : C21H16FN3OS
¿ëÇØµµ :Soluble in DMSO. |
S-3400 |
25mg, 50mg, 100mg, 200mg, 300mg, 500mg |
>99% |
[152121-47-6] |
| SC-58635 |
Celecoxib, C-1502 ÂüÁ¶ |
| SDZ-ASM-981 |
Pimecrolimus, P-6040 ÂüÁ¶ |
| SDZ-RAD |
Everolimus, E-4040 ÂüÁ¶ |
| Seliciclib |
Roscovitine, Free Base, R-1234 ÂüÁ¶ |
| SILA 9268A |
Rapamycin, R-5000 ÂüÁ¶ |
| Sirolimus |
Rapamycin, R-5000 ÂüÁ¶ |
| SKI-606 |
Bosutinib, Free Base, B-1709 |
| SNDX-275 |
Entinostat, Free Base E-3866 ÂüÁ¶ |
| Solexa |
Celecoxib, C-1502 ÂüÁ¶ |
|
Sorafenib, Free Base
À̸í : [Bay 43-9006] [Nexavar]
ºÐÀÚ·® : 464.82 ; ºÐÀÚ½Ä : C21H16ClF3N4O3
¿ëÇØµµ :Soluble in DMSO at 200 mg/mL; soluble in ethanol at 3.3 mg/mL with warming; very poorly soluble in water; maximum solubility in plain water is estimated to be about 10-50 ¥ìM; buffers, serum, or other additives may increase or decrease the aqueous solubility. |
S-8599 |
300mg, 500mg, 1g, 2g, 5g, 10g, 25g |
>99% |
[284461-73-0] |
|
Sorafenib, p-Toluenesulfonate Salt
À̸í : [Sorafenib Tosylate] [Bay 43-9006] [Nexavar]
ºÐÀÚ·® : 637.03 ; ºÐÀÚ½Ä : C21H16ClF3N4O3.C7H8O3S
¿ëÇØµµ :Very soluble in DMSO, up to about 200 mg/mL; very poorly soluble in water or ethanol. |
S-8502 |
300mg, 500mg, 1g, 2g, 5g, 10g, 25g |
>99% |
[475207-59-1] |
| Sorafenib Tosylate |
Sorafenib, p-Toluenesulfonate Salt, S-8502 ÂüÁ¶ |
|
SP600125
À̸í : [Anthra(1,9-cd)pyrazol-6(2H)-one] [1,9-Pyrazoloanthrone] [Anthrapyrazolone] [JNK Inhibitor II] [SAPK Inhibitor II]
ºÐÀÚ·® : 220.23; ºÐÀÚ½Ä : C14H8N2O
¿ëÇØµµ :Prepare initial stock solutions in DMSO (soluble at 65 mg/mL) for in vitro use; solubility in ethanol or water is low. |
S-7979 |
300mg, 1g, 2g, 5g |
>99% |
[129-56-6] |
| Sprycel |
Dasatinib, Free Base, D-3307 ÂüÁ¶ |
| SR-11247 |
Bexarotene, Free Acid, B-2422 ÂüÁ¶ |
Stauprimide
À̸í :[N-Benzoyl-7-oxostaurosporine]
ºÐÀÚ·® : ; 584.62 ºÐÀÚ½Ä : C35H28N4O5
¿ëÇØµµ : Soluble in DMSO at 100 mg/mL; very poorly soluble in ethanol; very poorly soluble in water; maximum solubility in plain water is estimated to be about 1-10 ¥ìM; buffers, serum, or other additives may increase or decrease the aqueous solubility. |
S-9344 |
1mg, 5mg, 10mg, 25mg, 50mg, 100mg |
>99% |
[154589-96-5] |
|
Staurosporine, Free Base
À̸í : [Antibiotic AM-2282]
ºÐÀÚ·® : 466.53 ; ºÐÀÚ½Ä : C28H26N4O3
¿ëÇØµµ :Soluble in DMSO or ethanol; insoluble in water. |
S-9300 |
1 mg, 5mg, 10mg, 25mg, 100mg, 300mg |
>99% |
[62996-74-1] |
| Staurosporine Aglycone |
K-252c, . K-9609 ÂüÁ¶ |
| Staurosporinone |
K-252c, K-9609 ÂüÁ¶ |
| STI-571 |
Imatinib, Methanesulfonate Salt,I-5508 ÂüÁ¶ |
| SU-11248 |
Sunitinib, Malate Salt, S-8803, S-8877 ÂüÁ¶ |
| Suberanilohydroxamic Acid |
VorinostatV-8477 ÂüÁ¶ |
| Suberoylanilide Hydroxamic Acid |
Vorinostat V-84777 ÂüÁ¶ |
|
Sunitinib, Free Base
À̸í : [SU-11248] [Sutent] [PHA-290940AD] [PNU-290940AD]
ºÐÀÚ·® : 398.47 ; ºÐÀÚ½Ä : C22H27FN4O2
¿ëÇØµµ :Soluble in DMSO at 40 mg/mL; soluble in ethanol at 1.4 mg/mL; very poorly soluble in water; maximum solubility in plain water is estimated to be about 10-20 ¥ìM; buffers, serum, or other additives may increase or decrease the aqueous solubility. |
S-8877 |
300mg, 500mg, 1g, 2g, 5g, 10g, 25g |
>99% |
[557795-19-4] |
| Sunitinib Maleate |
Sunitinib, Malate Salt S-8803 ÂüÁ¶ |
|
Sunitinib, Malate Salt
À̸í : [Sunitinib Maleate] [SU-11248] [Sutent] [PHA-290940AD] [PNU-290940AD]
ºÐÀÚ·® : 532.56 ; ºÐÀÚ½Ä : C22H27FN4O2.C4H6O5
¿ëÇØµµ :Soluble in DMSO at 40 mg/mL; very poorly soluble in ethanol; very poorly soluble in water; maximum solubility in plain water is estimated to be about 10-50 ¥ìM; buffers, serum, or other additives may increase or decrease the aqueous solubility. |
S-8803 |
300mg, 500mg , 1g, 2g, 5g, 10g, 25g |
>99% |
[341031-54-7] |
| Sutent |
Sunitinib, Malate Salt, S-8803, S-8877 ÂüÁ¶ |
| Synergisidin |
Brefeldin A, B-8500 ÂüÁ¶ |
| Tacedinaline |
CI-994, Free Base C-2606 ÂüÁ¶ |
| Tacrolimus |
FK-506, F-4900 ÂüÁ¶ |
| TAK-165 |
Mubritinb M-5602 ÂüÁ¶ |
|
Tandutinib, Free Base
À̸í : [MLN518] [CT53518]
ºÐÀÚ·® : 562.70 ºÐÀÚ½Ä : C31H42N6O4
¿ëÇØµµ :Soluble in DMSO at 25 mg/mL with warming; soluble in ethanol at 25 mg/mL with warming; very poorly soluble in water; maximum solubility in plain water is estimated to be about 50-100 ¥ìM; buffers, serum, or other additives may increase or decrease the aqueous solubility. |
T-7802 |
25mg, 50mg, 100mg, 200mg, 500mg, 1g |
>99% |
[387867-13-2] |
| Tanespimycin |
17-AAG, A-6880 ÂüÁ¶ |
| Tarceva |
Erlotinib, Hydrochloride Salt, E-4007 ÂüÁ¶ |
| Targretin |
Bexarotene, Free Acid, B-2422 ÂüÁ¶ |
| Targretyn |
Bexarotene, Free Acid, B-2422 ÂüÁ¶ |
| Targrexin |
Bexarotene, Free Acid, B-2422 ÂüÁ¶ |
| Tasigna |
Nilotinib, Free Base, N-8207 ÂüÁ¶ |
| Tasocitinib |
CP-690550, Free Base C-1377 ÂüÁ¶ |
| Taxol |
Paclitaxel, P-9600 ÂüÁ¶ |
| Taxotere |
Docetaxel, D-1000 ÂüÁ¶ |
| Telatinib |
17-AAG, A-6880 ÂüÁ¶ |
|
Temsirolimus
À̸í : [CCI-779] [Torisel]
ºÐÀÚ·® : 1030.29; ºÐÀÚ½Ä : C56H87NO16
¿ëÇØµµ :Soluble in DMSO at 200 mg/mL; soluble in ethanol at 200 mg/mL; very poorly soluble in water; maximum solubility in plain water is estimated to be about 10-20 ¥ìM; buffers, serum, or other additives may increase or decrease the aqueous solubility. |
T-8040 |
10mg, 25mg, 50mg, 100mg, 200mg, 300mg, 500mg , 1g |
>99% |
[162635-04-3] |
| 12-O-Tetradecanoylphorbol 13-Acetate |
Phorbol 12-Myristate 13-Acetate, P-1680 ÂüÁ¶ |
| 4¥á-12-O-Tetradecanoylphorbol 13-Acetate |
4¥á-Phorbol 12-Myristate 13-Acetate, P-8880 ÂüÁ¶ |
|
Thapsigargin
ºÐÀÚ·® : 650.75 ; ºÐÀÚ½Ä : C34H50O12
¿ëÇØµµ :Soluble in DMSO or ethanol. ÁÖÀÇ:Highly irritant to skin and mucous membranes. SPECIAL HAZARD: TUMOR PROMOTER. Gloves and mask should be worn when using this compound. Care must be taken to prevent contact through all routes of exposure. |
T-3250 |
1 mg, 5mg, 10mg, 25mg |
>99% |
[67526-95-8] |
| Tifolar |
Pemetrexed, Disodium Salt, HeptahydrateP-7177ÂüÁ¶ |
|
Tinyatoxin
À̸í : [TNX] [TYX]
ºÐÀÚ·® : 598.68 ; ºÐÀÚ½Ä : C36H38O8
¿ëÇØµµ :Soluble in DMSO or ethanol. |
T-5096 |
1 mg, 5mg |
>99% |
[58821-95-7] |
| TKI-258 |
Dovitinib, Free Base, D-3608 ÂüÁ¶ |
| TNX |
Tinyatoxin, T-5096 ÂüÁ¶ |
| Topotecin |
Irinotecan, Hydrochloride Salt, Trihydrate, I-4122 ÂüÁ¶ |
| Torisel |
Temsirolimus, T-8040 ÂüÁ¶ |
|
Tozasertib, Free Base
À̸í : [VX-680] [MK-0457] [VX6]
ºÐÀÚ·® : 464.59 ; ºÐÀÚ½Ä : C23H28N8OS
¿ëÇØµµ :Soluble in DMSO. |
T-2304 |
10mg, 25mg, 50mg, 100mg, 200mg, 300mg, 500mg, 1g, 2g |
>99% |
[639089-54-6] |
| TPA |
Phorbol 12-Myristate 13-Acetate, P-1680 ÂüÁ¶ |
| 4¥á-TPA |
4¥á-Phorbol 12-Myristate 13-Acetate, P-8880 ÂüÁ¶ |
| Transplatin |
Oxaliplatin, O-7111 ÂüÁ¶ |
| 4',5,7-Trihydroxyisoflavone |
Genistein, G-6055 ÂüÁ¶ |
| Tykerb |
Lapatinib, Di-p-Toluenesulfonate Salt, L-4804 ÂüÁ¶ |
|
Tyrphostin AG 490
À̸í : [AG 490] [Tyrphostin B42] [N-Benzyl-3,4-dihydroxy-benzylidenecyanoacetamide]
ºÐÀÚ·® : 294.30 ; ºÐÀÚ½Ä : C17H14N2O3
¿ëÇØµµ :Soluble in DMSO. |
T-9142 |
25mg, 100mg, 300mg, 1g |
>99% |
[134036-52-5] |
|
Tyrphostin AG 1478, Free Base
À̸í : [AG 1478]
ºÐÀÚ·® : 315.75 ; ºÐÀÚ½Ä : C16H14ClN3O2
¿ëÇØµµ :Soluble in DMSO, to about 60 mg/ml; poorly soluble in ethanol. |
T-7310 |
25mg, 100mg, 500mg, 1g |
>99% |
[175178-82-2] |
| Tyrphostin B42 |
Tyrphostin AG 490, T-9142 ÂüÁ¶ |
| Tyverb |
Lapatinib, Di-p-Toluenesulfonate Salt, L-4804 ÂüÁ¶ |
| TYX |
Tinyatoxin, T-5096 ÂüÁ¶ |
|
U0126
À̸í : [1,4-Diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)-butadiene]
ºÐÀÚ·® : 380.49 ; ºÐÀÚ½Ä : C18H16N6S2
¿ëÇØµµ :Soluble in DMSO. |
U-6770 |
25mg, 100mg, 300mg, 1g, 2g |
>99% |
[109511-58-2] |
| U-29135 |
Geldanamycin, G-4500 ÂüÁ¶ |
| U-101440E |
Irinotecan, Hydrochloride Salt, Trihydrate, I-4122 ÂüÁ¶ |
|
Vandetanib, Free Base
À̸í : [Zactima] [ZD6474]
ºÐÀÚ·® : 475.35 ; ºÐÀÚ½Ä : C22H24BrFN4O2
¿ëÇØµµ :Soluble in DMSO at 30 mg/mL; soluble in ethanol at 10 mg/mL with warming; very poorly soluble in water; maximum solubility in plain water is estimated to be about 10-20 ¥ìM; buffers, serum, or other additives may increase or decrease the aqueous solubility. |
V-9402 |
50mg, 100mg, 200mg, 300mg, 500mg, 1g, 2g |
>99% |
[443913-73-3] |
|
Vargatef, Free Base
À̸í : [BIBF1120]
ºÐÀÚ·® : 539.62 ; ºÐÀÚ½Ä : C31H33N5O4
¿ëÇØµµ :Soluble in DMSO. |
V-9077 |
5mg, 10mg, 25mg, 50mg, 100mg, 200mg, 1g,2g |
>99% |
[928326-83-4] |
|
Vatalanib, Dihydrochloride Salt
À̸í : [CGP-79787] [PTK 787] [ZK222584]
ºÐÀÚ·® : 419.73 ; ºÐÀÚ½Ä : C20H15ClN4.2HCl
¿ëÇØµµ :Soluble in water, up to about 100 mg/mL; very poorly soluble in ethanol; slightly soluble in DMSO, up to about 10-20 mg/mL after heating. |
V-8303 |
25mg, 100mg, 200mg , 300mg, 500mg , 1g, 2g |
>99% |
[212141-51-0] |
| Velcade |
Bortezomib, B-1408 ÂüÁ¶ |
Vorinostat 
À̸í :
ºÐÀÚ·® : ; ºÐÀÚ½Ä :
¿ëÇØµµ : |
V-8477 |
100mg, 250mg, 500mg, 1g, 2g, 5g, 10g |
>99% |
[19545-26-7] |
| VX6 |
Tozasertib, Free Base, T-2304 ÂüÁ¶ |
| VX-680 |
Tozasertib, Free Base, T-2304 ÂüÁ¶ |
VX-702, Free Base 
À̸í :
ºÐÀÚ·® : ; ºÐÀÚ½Ä :
¿ëÇØµµ : |
V-9366 |
5mg, 10mg, 25mg, 50mg, 100mg, 200mg |
>99% |
[19545-26-7] |
|
Wortmannin
À̸í : [KY 12420]
ºÐÀÚ·® : 428.43 ; ºÐÀÚ½Ä : C23H24O8
¿ëÇØµµ :Soluble in DMSO or ethanol; very poorly soluble in water; maximum solubility in plain water is estimated to be about 10-50 ¥ìM; buffers, serum, or other additives may increase or decrease the aqueous solubility. |
W-2990 |
10mg, 25mg, 100mg, 300mg |
>99% |
[19545-26-7] |
| Xabine |
Capecitabine C-2799 ÂüÁ¶ |
| Xarelto |
RivaroxabanR-7199 ÂüÁ¶ |
| Xeloda |
Capecitabine, C-2799 ÂüÁ¶ |
| YM-177 |
Celecoxib, C-1502 ÂüÁ¶ |
| Zactima |
Vandetanib, Free Base, V-9402 ÂüÁ¶ |
| ZD-1839 |
Gefitinib, Free Base, G-4408 ÂüÁ¶ |
| ZD6474 |
Vandetanib, Free Base, V-9402 ÂüÁ¶ |
| ZK222584 |
Vatalanib, Dihydrochloride Salt, V-8303 ÂüÁ¶ |
| Zolinza |
Vorinostat V-8477 ÂüÁ¶ |
|
Zotarolimus
À̸í : [ABT-578] [40-Epi-(N1-tetrazolyl)-rapamycin]
ºÐÀÚ·® : 966.21; ºÐÀÚ½Ä : C52H79N5O12
¿ëÇØµµ :Soluble in DMSO. |
Z-9040 |
5mg, 25mg, 100mg |
>98% |
[221877-54-9] |
|
ZSTK474, Free Base
ºÐÀÚ·® : 417.41 ; ºÐÀÚ½Ä : C19H21F2N7O2
¿ëÇØµµ :Soluble in DMSO at 20 mg/mL; soluble in ethanol at 2.5 mg/mL with warming; very poorly soluble in water; maximum solubility in plain water is estimated to be about 1-5 ¥ìM; buffers, serum, or other additives may increase or decrease the aqueous solubility. |
Z-1066 |
100mg, 200mg, 300mg, 1g,2g, 5g |
>99% |
[475110-96-4] |
|